The Latest in FDA Evaluations and Research

FDA News


Related Topics: FDA News, Disability Nexus

News Feed Item

Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference

Live Webcast on Wednesday, September 10, at 2:55 p.m. EST

GERMANTOWN, Md., Sept. 5, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 16th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 10, at 2:55 p.m. EST. Garr will provide an overview of the company's NSI-566 cell therapy clinical trials for ALS, which concluded final Phase II treatments in July, and chronic spinal cord injury, which launched in August with Phase I patient recruitment at the University of California, San Diego. He will also provide an overview of Neuralstem's neurogenic small molecule compound, NSI-189, Phase Ia and Ib major depressive disorder (MDD) trial results, and the NSI-189/MDD Phase II study expected to commence in late first quarter 2015.

To view the live webcast, and to pre-register for viewing, visit Neuralstem's Investor Center at www.neuralstem.com, or: http://wsw.com/webcast/rrshq24/CUR. Mr. Garr's presentation will occur in the Holmes 1 Salon, 4th Floor, of the New York Palace Hotel in New York City, site of the conference (www.rodm.com).

About Neuralstem

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, concluded final surgeries in July 2014. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received approvals from the FDA and the Institutional Review Board of University of California, San Diego, to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions. The company has completed Phase Ia and Ib trials evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD), and is expecting to launch a Phase II NSI-189/MDD study in 2015. Additional indications might include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information:

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2013 and Form 10Q, for the period ended June 30, 2014.

Neuralstem Logo.

Logo - http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO

SOURCE Neuralstem, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.